Narang S, Sood S, Kaur B, Singh R, Mallik A, Kaur J
Government Medical College Hospital, Chandigarh, India.
Nepal J Ophthalmol. 2012 Jan-Jun;4(1):23-8. doi: 10.3126/nepjoph.v4i1.5846.
Lipid-lowering drugs preserve vision and reduce the risk of hard exudates in clinically-significant macular edema(CSME) in diabetics with an abnormal lipid profile. But their role in reducing CSME in diabetics with a normal lipid profile is not yet known.
To evaluate the role of atorvastatin in CSME in diabetics with a normal lipid profile.
A prospective, randomized clinical trial was carried out. Thirty CSME patients with a normal lipid profile were randomly divided into Group A and B. Atorvastatin had been started in Group A four weeks prior to laser treatment. The main outcome measures were any improvement or deterioration in visual acuity and macular edema and hard exudates at six months follow-up.
Both the groups were compared using unpaired t test for quantitative parameters and chi-square test for qualitative parameters. A p value of less than 0.05 was taken as significant.
Visual acuity, macular edema and hard exudates resolution was not significantly different in the two groups (P = 0.14, 0.62, 0.39 respectively).
Atorvastatin does not affect treatment outcome in CSME with a normal lipid profile over a short term follow-up.
降脂药物可保护脂质谱异常的糖尿病患者的视力，并降低其发生临床显著性黄斑水肿（CSME）时出现硬性渗出的风险。但它们在脂质谱正常的糖尿病患者中对降低CSME的作用尚不清楚。
评估阿托伐他汀在脂质谱正常的糖尿病患者的CSME中的作用。
开展一项前瞻性随机临床试验。30例脂质谱正常的CSME患者被随机分为A组和B组。A组在激光治疗前四周开始使用阿托伐他汀。主要观察指标为随访六个月时视力、黄斑水肿及硬性渗出的任何改善或恶化情况。
两组定量参数采用非配对t检验比较，定性参数采用卡方检验比较。p值小于0.05被视为具有显著性。
两组的视力、黄斑水肿及硬性渗出消退情况无显著差异（分别为P = 0.14、0.62、0.39）。
在短期随访中，阿托伐他汀对脂质谱正常的CSME患者的治疗效果无影响。
